the Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Here Today, Gone Tomorrow?
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The concept of the epithelial-to-mesenchymal transition (EMT) has taken the fibrosis world by storm. It is perhaps the most intriguing and controversial of recent hypotheses on the mechanism of fibrosis that injured epithelial cells, via an EMT, contribute directly to matrix deposition and repair. Originally invoked as a source of collagen-producing cells in the kidney,1, 2 EMT is now thought to occur in fibrosis of the lung and, through the transition of both hepatocytes and cholangiocytes, the liver.3-5 This has important theoretical and practical implications for studying fibrosis: EMT provides a potential mechanism for the rapid mobilization of large numbers of fibrogenic cells after injury, and it proceeds by unique signaling programs that may prove to be viable therapeutic targets. EMT occurs when epithelial cells lose key epithelial characteristics, including apical-basal polarity, intercellular adhesion complexes, and adherence to a basal basement membrane, while simultaneously becoming motile, invasive, and, in some cases, fibrogenic.6, 7 One recently proposed scheme divides EMT into three distinct categories: type 1 occurring in development, type 2 in fibrosis, and type 3 in cancer and metastasis.6, 8 Type 1 EMT yields mesenchymal cells whereas type 2 yields fibroblasts which produce collagen, although they may or may not later become myofibroblasts.8 This is an important point when considering fibrosis in the liver and other organs, because there is an abundance of data implicating α-smooth muscle actin (α-SMA)-positive myofibroblasts in matrix deposition.9, 10 As discussed below, many studies on EMT in fibrosis have failed to rigorously define EMT or to reconcile evidence of EMT with previous observations about the central role of myofibroblasts in fibrosis. Additionally, high-level collagen expression is not synonymous with a mesenchymal or fibroblast phenotype, although it is unquestionably the characteristic most relevant to fibrosis. EMT in fibrosis, although poorly defined in the literature, should incorporate two key elements: that cells lose their epithelial identity, and that in this new state they deposit relevant amounts of collagen. In the absence of any suggestion that nonfibrogenic transitioned cells have a significant role in fibrosis, convincing studies of EMT need to address both points. The identification of EMT in vivo is at the heart of the controversy over its role in fibrosis. Demonstrating motility, loss of cell-cell adhesion, and basement membrane breakdown in tissue samples is difficult given current methods, and many investigators have turned to surrogate markers of the epithelial and mesenchymal states as a means of defining EMT. Many of the markers in common use, however, are problematic because of a lack of specificity (e.g., vimentin) or because it is technically challenging to assess potentially subtle differences in localization or expression (e.g., epithelial markers like E-cadherin). The expression of fibroblast-specific protein 1 (FSP1, also referred to as S100A4) in cells with epithelial markers has been widely used to define EMT in vivo. This protein is reported to be specific for fibroblasts and to play a causal role in EMT.2 Significant data are emerging, however, questioning its specificity. In the kidney, carefully performed work suggests that FSP1 is a marker not of fibroblasts but rather of leukocytes and other, nonfibroblastic cell types.9, 11 This raises questions about the validity of studies postulating EMT on the basis of FSP1 staining, which includes most studies of EMT in liver fibrosis. Against this backdrop, Taura and colleagues used definitive marker analyses to readdress the question of whether hepatocytes undergo EMT and deposit collagen in the injured liver.12 In their article in this issue of HEPATOLOGY, they first investigated convincing reports that EMT occurs in hepatocytes in vitro. Several groups previously demonstrated that primary mouse hepatocytes, when treated with the classical EMT inducer transforming growth factor-β (TGF-β) or isolated from cirrhotic livers and cultured, adopt a fibroblast-like morphology, with decreased membrane-bound E-cadherin and increased expression of vimentin and type I collagen (although not the myofibroblast marker α-SMA).13-15 Because precursor cells may lose epithelial markers during EMT, one group used primary hepatocytes carrying a permanent β-galactosidase (β-Gal) tag to show that TGF-β treatment resulted in increased motility and FSP1 expression of cells clearly identified as hepatocytes.14 Taura et al. provide clear evidence that these examples of hepatocyte EMT in vitro are artifacts of cell culture.12 The group generated triple transgenic mice (Rosa26–stop–β-Gal; Albumin-Cre; Col I-GFP) which permanently and heritably express β-galactosidase in hepatocytes and activate green fluorescent protein (GFP) in cells expressing type I collagen. In their first experiment, they isolated hepatocytes from
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers for epithelial-mesenchymal transitions
Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299 · cited 2×
“One recently proposed scheme divides EMT into three distinct categories: type 1 occurring in development, type 2 in fibrosis, and type 3 in cancer and metastasis.(6,8) Type 1 EMT yields mesenchymal cells whereas type 2 yields fibroblasts which produce collagen, although they may or may not later become myofibroblasts.”
Background
Cited by
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Hepatic stellate cells in liver development, regeneration, and cancer
Yin, C., Evason, K. J., Asahina, K., & Stainier, D. Y. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66369 · Cited by 719
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Host Responses in Tissue Repair and Fibrosis
Duffield, J. S., Lupher, M., Thannickal, V. J., & Wynn, T. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163930 · Cited by 624
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Metadata
- Authors
- Wells, R. G.
- Venue
- Hepatology
- Published
- 2010-03
- Volume
- 51
- Issue
- 3
- Pages
- 737-740
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2063995419
- Cited by
- 83
- References
- 1
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.